|
1.
|
Oken MM, Hocking WG, Kvale PA, et al:
Screening by chest radiograph and lung cancer mortality: the
Prostate, Lung, Colorectal, and Ovarian (PLCO) randomized trial.
JAMA. 306:1865–1873. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2.
|
Ferlay J, Parkin DM and Steliarova-Foucher
E: Estimates of cancer incidence and mortality in Europe in 2008.
Eur J Cancer. 46:765–781. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3.
|
Huang TW, Hsieh CM, Chang H, et al:
Standard uptake value of positron emission tomography in clinical
stage I lung cancer: clinical application and pathological
correlation. Eur J Cardiothorac Surg. 41:869–873. 2012. View Article : Google Scholar
|
|
4.
|
Sawabata N, Maeda H, Yokota S, et al:
Postoperative serum carcinoembryonic antigen levels in patients
with pathologic stage IA nonsmall cell lung carcinoma: subnormal
levels as an indicator of favorable prognosis. Cancer. 101:803–809.
2004. View Article : Google Scholar
|
|
5.
|
Ardizzoni A, Cafferata MA, Tiseo M, et al:
Decline in serum carcinoembryonic antigen and cytokeratin 19
fragment during chemotherapy predicts objective response and
survival in patients with advanced nonsmall cell lung cancer.
Cancer. 107:2842–2849. 2006. View Article : Google Scholar
|
|
6.
|
Dehing-Oberije C, Aerts H, Yu S, et al:
Development and validation of a prognostic model using blood
biomarker information for prediction of survival of non-small-cell
lung cancer patients treated with combined chemotherapy and
radiation or radiotherapy alone (NCT00181519, NCT00573040, and
NCT00572325). Int J Radiat Oncol Biol Phys. 81:360–368. 2011.
|
|
7.
|
Pujol JL, Molinier O, Ebert W, et al:
CYFRA 21-1 is a prognostic determinant in non-small-cell lung
cancer: results of a meta-analysis in 2063 patients. Br J Cancer.
90:2097–2105. 2004.PubMed/NCBI
|
|
8.
|
Grunnet M and Sorensen JB:
Carcinoembryonic antigen (CEA) as tumor marker in lung cancer. Lung
Cancer. 76:138–143. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9.
|
Arrieta O, Saavedra-Perez D, Kuri R, et
al: Brain metastasis development and poor survival associated with
carcinoembryonic antigen (CEA) level in advanced non-small cell
lung cancer: a prospective analysis. BMC Cancer. 9:1192009.
View Article : Google Scholar : PubMed/NCBI
|
|
10.
|
Emin Erbaycu A, Gunduz A, Batum O, Zeren
Ucar Z, Tuksavul F and Zeki Guglu S: Pre-treatment and
treatment-induced neuron-specific enolase in patients with
small-cell lung cancer: an open prospective study. Arch
Broncopneumol. 46:364–369. 2010.(In Spanish).
|
|
11.
|
Jin B, Huang AM, Zhong RB and Han BH: The
value of tumor markers in evaluating chemotherapy response and
prognosis in Chinese patients with advanced non-small cell lung
cancer. Chemotherapy. 56:417–423. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
12.
|
Travis WD: Pathology and genetics: tumours
of the lung, pleura, thymus and heart. 7. Iarc; 2004
|
|
13.
|
Eisenhauer EA, Therasse P, Bogaerts J, et
al: New response evaluation criteria in solid tumours: revised
RECIST guideline (version 1.1). Eur J Cancer. 45:228–247. 2009.
View Article : Google Scholar
|
|
14.
|
Seemann MD, Beinert T, Fürst H and Fink U:
An evaluation of the tumour markers, carcinoembryonic antigen
(CEA), cytokeratin marker (CYFRA 21-1) and neuron-specific enolase
(NSE) in the differentiation of malignant from benign solitary
pulmonary lesions. Lung Cancer. 26:149–155. 1999. View Article : Google Scholar
|
|
15.
|
Edelman MJ, Hodgson L, Rosenblatt PY, et
al: CYFRA 21-1 as a prognostic and predictive marker in advanced
non-small-cell lung cancer in a prospective trial: CALGB 150304. J
Thorac Oncol. 7:649–654. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16.
|
Alataş F, Alataş O, Metintaş M, Colak O,
Harmanci E and Demir S: Diagnostic value of CEA, CA 15-3, CA 19-9,
CYFRA 21-1, NSE and TSA assay in pleural effusions. Lung Cancer.
31:9–16. 2001.PubMed/NCBI
|
|
17.
|
Li CG, Huang XE, Xu L, Li Y and Lu YY:
Clinical application of serum tumor associated material (TAM) from
non-small cell lung cancer patients. Asian Pac J Cancer Prev.
13:301–304. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18.
|
Holdenrieder S, von Pawel J, Dankelmann E,
et al: Nucleosomes and CYFRA 21-1 indicate tumor response after one
cycle of chemotherapy in recurrent non-small cell lung cancer. Lung
Cancer. 63:128–135. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
19.
|
Holdenrieder S, von Pawel J, Dankelmann E,
et al: Nucleosomes, ProGRP, NSE, CYFRA 21-1, and CEA in monitoring
first-line chemotherapy of small cell lung cancer. Clin Cancer Res.
14:7813–7821. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
20.
|
Alm El-Din MA, Farouk G, Nagy H, Abd
Elzaher A and Abo El-Magd GH: Cytokeratin-19 fragments, nucleosomes
and neuron-specific enolase as early measures of chemotherapy
response in non-small cell lung cancer. Int J Biol Marker.
27:e139–e146. 2012.PubMed/NCBI
|
|
21.
|
Kulpa J, Wójcik E, Reinfuss M and
Kolodziejski L: Carcinoembryonic antigen, squamous cell carcinoma
antigen, CYFRA 21-1, and neuron-specific enolase in squamous cell
lung cancer patients. Clin Chem. 48:1931–1937. 2002.PubMed/NCBI
|
|
22.
|
Song WA, Liu X, Tian XD, et al: Utility of
squamous cell carcinoma antigen, carcinoembryonic antigen, Cyfra
21-1 and neuron specific enolase in lung cancer diagnosis: a
prospective study from China. Chin Med J (Engl). 124:3244–3248.
2011.PubMed/NCBI
|
|
23.
|
Sheard MA, Vojtesek B, Simickova M and
Valik D: Release of cytokeratin-18 and -19 fragments (TPS and CYFRA
21-1) into the extracellular space during apoptosis. J Cell
Biochem. 85:670–677. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
24.
|
Matsuoka K, Sumitomo S, Nakashima N,
Nakajima D and Misaki N: Prognostic value of carcinoembryonic
antigen and CYFRA21-1 in patients with pathological stage I
non-small cell lung cancer. Eur J Cardiothorac Surg. 32:435–439.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
25.
|
Tomita M, Shimizu T, Ayabe T, Yonei A and
Onitsuka T: Prognostic significance of tumour marker index based on
preoperative CEA and CYFRA 21-1 in non-small cell lung cancer.
Anticancer Res. 30:3099–3102. 2010.PubMed/NCBI
|
|
26.
|
Tomida M, Mikami I, Takeuchi S, Nishimura
H and Akiyama H: Serum levels of nicotinamide N-methyltransferase
in patients with lung cancer. J Cancer Res Clin Oncol.
135:1223–1229. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
27.
|
Iwanicki-Caron I, Di Fiore F, Roque I, et
al: Usefulness of the serum carcinoembryonic antigen kinetic for
chemotherapy monitoring in patients with unresectable metastasis of
colorectal cancer. J Clin Oncol. 26:3681–3686. 2008. View Article : Google Scholar
|
|
28.
|
Konstantopoulos K and Thomas SN: Cancer
cells in transit: the vascular interactions of tumor cells. Annu
Rev Biomed Eng. 11:177–202. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
29.
|
Thomas SN, Zhu F, Schnaar RL, Alves CS and
Konstantopoulos K: Carcinoembryonic antigen and CD44 variant
isoforms cooperate to mediate colon carcinoma cell adhesion to E-
and L-selectin in shear flow. J Biol Chem. 283:15647–15655. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
30.
|
Thomas SN, Tong Z, Stebe KJ and
Konstantopoulos K: Identification, characterization and utilization
of tumor cell selectin ligands in the design of colon cancer
diagnostics. Biorheology. 46:207–225. 2009.PubMed/NCBI
|
|
31.
|
Nuñez GR, Ito C and Del Giglio A:
Increased serum CA-125 levels in patients with lung cancer post
thoracotomy. South Med J. 102:427–428. 2009.PubMed/NCBI
|
|
32.
|
Li X, Asmitananda T, Gao L, et al:
Biomarkers in the lung cancer diagnosis: a clinical perspective.
Neoplasma. 59:500–507. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
33.
|
Muley T, Fetz TH, Dienemann H, et al:
Tumor volume and tumor marker index based on CYFRA 21-1 and CEA are
strong prognostic factors in operated early stage NSCLC. Lung
Cancer. 60:408–415. 2008.PubMed/NCBI
|
|
34.
|
Ma S, Shen L, Qian N and Chen K: The
prognostic values of CA125, CA19.9, NSE, AND SCC for stage I NSCLC
are limited. Cancer Biomark. 10:155–162. 2011.PubMed/NCBI
|
|
35.
|
Wang Y, Tang D, Sui A, et al: Prognostic
significance of NSE mRNA in advanced NSCLC treated with gefitinib.
Clin Transl Oncol. 15:384–390. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
36.
|
Gridelli C, Rossi A and Maione P:
Treatment of non-small-cell lung cancer: state of the art and
development of new biologic agents. Oncogene. 22:6629–6638. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
37.
|
Wang J, Zhang N, Li B, et al: Decline of
serum CYFRA21-1 during chemoradiotherapy of NSCLC: a probable
predictive factor for tumor response. Tumour Biol. 32:689–695.
2011. View Article : Google Scholar : PubMed/NCBI
|
